Roland Walter

Adjunct Professor, Epidemiology
Professor, Medicine - Hematology
Adjunct Professor, Laboratory Medicine and Pathology



MD Medicine, University of Zurich (Switzerland), 1997
PhD Experimental Pathology, University of Washington, 2006
MS Epidemiology (Clinical Research), University of Washington, 2011



Fred Hutchinson Cancer Research Center
100 Fairview Ave. N., D2-190
Seattle, WA 98109
View Website »


My research is focused on acute myeloid leukemia (AML). I am particularly interested in improving antibody-based therapies, both by optimizing the efficacy/safety profile of existing therapeutics and through the preclinical and early clinical development of novel antigen-directed immunotherapies. As examples of latter efforts, my lab has contributed to candidate drug identification and preclinical development of 5 novel agents that have subsequently advanced to clinical testing (SGN-CD33A, SGN-CD123A, AMG 330, AMV-564, and APVO436). A major area of focus of our research lies in the delineation of the mechanisms of action and resistance that are relevant for antibody-based AML therapeutics and the rational development of combination therapies that can overcome drug resistance. Many of my studies conducted over the last 15+ years have aimed at optimizing CD33-targeted and, more recently, CD123-targeted therapies. In clinical studies, I conduct trials testing novel treatments and innovative care approaches for AML patients. Furthermore, in collaborative research, I use large patient datasets to develop and improve diagnostic and prognostic tools for people with AML.

Research Areas

Research Interests

  • Acute myeloid leukemia
  • CD33
  • Immunotherapy of AML
  • Clinical trials in AM
  • Measurable residual disease (MRD)
  • Predictive modeling

Recent Publications (PubMed)

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
(2022 Jun 14)
Cancers (Basel) 14(12):
Godwin CD, Rodríguez-Arbolí E, Othus M, Halpern AB, Appelbaum JS, Percival MM, Hendrie PC, Oehler VG, Keel SB, Abkowitz JL, Cooper JP, Cassaday RD, Estey EH, Walter RB

Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making.
(2022 Jun 13)
Oncol Ther
LeBlanc TW, Russell NH, Hernandez-Aldama L, Panter C, Bell TJ, Welch V, Vega DM, O'Hara L, Stein J, Barclay M, Peloquin F, Brown A, Healy J, Morgan L, Gater A, Hohman R, Amer K, Maze D, Walter RB

Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.
(2022 Jun 3)
Orvain C, Othus M, Johal G, Hunault-Berger M, Appelbaum FR, Walter RB

Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.
(2022 Jun)
Leukemia 36(6): 1485-1491
Laszlo GS, Orozco JJ, Kehret AR, Lunn MC, Huo J, Hamlin DK, Scott Wilbur D, Dexter SL, Comstock ML, O'Steen S, Sandmaier BM, Green DJ, Walter RB

Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
(2022 Jun)
Leukemia 36(6): 1563-1574
Zarling LC, Othus M, Sandmaier BM, Milano F, Schoch G, Davis C, Bleakley M, Deeg HJ, Appelbaum FR, Storb R, Walter RB

Show complete publication list

In the News

No news articles at this time.